Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
暂无分享,去创建一个
L. Pasqualucci | L. Farinelli | R. Rabadán | Joseph Chan | A. Kohlmann | T. Haferlach | B. Falini | A. Holmes | S. Schnittger | W. Kern | H. Klein | V. Trifonov | C. Haferlach | K. Kreuzer | M. Dugas | H. Serve | K. Goetze | F. Di Raimondo | D. Oruzio | A. Rambaldi | G. Specchia | Victoria A. Wells | R. Bassan | O. Spinelli | R. Rossi | L. De Carolis | E. Tiacci | V. Grossmann | A. Spanhol-Rosseto | A. Liso | M. Martelli | F. Fabbiano | S. Schindela | S. Baldoni | R. Peceny | M. Sborgia | Stefano Baldoni
[1] A. Kohlmann,et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories , 2011, Leukemia.
[2] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[3] Yong-mei Zhu,et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.
[4] T. Haferlach,et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. , 2011, Blood.
[5] N. Bolli,et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? , 2011, Blood.
[6] T. Haferlach,et al. A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. , 2011, Experimental hematology.
[7] A. Tefferi,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[8] T. Haferlach,et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. , 2010, Blood.
[9] N. Emi,et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. , 2010, Blood.
[10] B. Falini,et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. , 2010, Blood.
[11] Torsten Haferlach,et al. The role of multiparameter flow cytometry for disease monitoring in AML. , 2010, Best practice & research. Clinical haematology.
[12] T. Naoe,et al. Array-based genomic resequencing of human leukemia , 2010, Oncogene.
[13] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Tikhonova,et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.
[15] Robert E. Kingston,et al. Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.
[16] A. Kohlmann,et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.
[17] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[18] T. Haferlach,et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.
[19] Guoping Fan,et al. BCOR regulates mesenchymal stem cell function by epigenetic mechanisms , 2009, Nature Cell Biology.
[20] J. A. Wamstad,et al. Role of the Transcriptional Corepressor Bcor in Embryonic Stem Cell Differentiation and Early Embryonic Development , 2008, PloS one.
[21] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[22] Torsten Haferlach,et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.
[23] A. Melnick,et al. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. , 2008, Molecular cell.
[24] B. Löwenberg. Acute myeloid leukemia: the challenge of capturing disease variety. , 2008, Hematology. American Society of Hematology. Education Program.
[25] C. Sánchez,et al. Proteomics Analysis of Ring1B/Rnf2 Interactors Identifies a Novel Complex with the Fbxl10/Jhdm1B Histone Demethylase and the Bcl6 Interacting Corepressor*S , 2007, Molecular & Cellular Proteomics.
[26] J. A. Wamstad,et al. Characterization of Bcor expression in mouse development. , 2007, Gene expression patterns : GEP.
[27] J. A. Wamstad,et al. Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets , 2006, Molecular and Cellular Biology.
[28] Yong Wang,et al. Corrigendum: Genome sequencing in microfabricated high-density picolitre reactors , 2006, Nature.
[29] W. Hiddemann,et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.
[30] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[31] Natalia Meani,et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.
[32] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[33] W. Hiddemann,et al. Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. , 2005, Haematologica.
[34] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[35] E. Seto,et al. Molecular Cloning and Functional Characterization of the Transcription Factor YY2* , 2004, Journal of Biological Chemistry.
[36] L. Biesecker,et al. Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR , 2004, Nature Genetics.
[37] G. Orphanides,et al. FACT Facilitates Transcription-Dependent Nucleosome Alteration , 2003, Science.
[38] R. Srinivasan,et al. The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor , 2003, Oncogene.
[39] Martin Dugas,et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .
[40] W. Hiddemann,et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases , 2002, Leukemia.
[41] J. Bennett,et al. B-Lymphoblastic Leukemia/Lymphoma , 2014 .
[42] E. Verdin,et al. BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.
[43] H. Willard,et al. A first-generation X-inactivation profile of the human X chromosome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] E. Seto,et al. Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23. , 1994, The Journal of biological chemistry.
[45] M. Plummer,et al. International agency for research on cancer. , 2020, Archives of pathology.